Literature DB >> 31188469

Effect of Body Weight on Risk-Benefit and Dosing Regimen Recommendation of Secukinumab for the Treatment of Moderate to Severe Plaque Psoriasis.

Jee Eun Lee1, Jie Wang1, Jeffry Florian1, Yow-Ming Wang1, David Kettl2, Kendall Marcus2, Amy Woitach2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31188469     DOI： 10.1002/cpt.1478

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  3 in total

1.  Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies.

Authors:  B Strober; A Menter; C Leonardi; K Gordon; J Lambert; L Puig; H Photowala; M Longcore; T Zhan; P Foley
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-03       Impact factor: 6.166

Review 2.  The Interrelations between Biological and Targeted Synthetic Agents Used in Inflammatory Joint Diseases, and Obesity or Body Composition.

Authors:  Eric Toussirot
Journal:  Metabolites       Date:  2020-03-13

Review 3.  Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis.

Authors:  Flavia Anghel; Diana Nitusca; Patricia Cristodor
Journal:  Life (Basel)       Date:  2021-11-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.